[1] Popova SN, Bergqvist M, Dimberg A, et al. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry[J]. Histopathology, 2014, 64(3): 365-379.
[2] Xu J, Xu W, Zhu J. Propofol suppresses proliferation and invasion of glioma cells by upregulating microRNA-218 expression[J]. Mol Med Rep, 2015, 12(4): 4815- 4820.
[3] Shi R , Wang PY, Li XY, et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients[J]. Oncotarget, 2015, 6(29): 26971-26981.
[4] Helseth R, Helseth E, Johannesen TB, et al. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme[J]. Acta Neurol Scand, 2010,122(3): 159-167.
[5] Chen X, Lu P, Chen L, et al. Perioperative propofol-paravertebral anesthesia decreases the metastasis and progression of breast cancer[J]. Tumor Biol, 2015, 36(11): 8259-8266.
[6] Wang ZT, Gong HY, Zheng F, et al. Propofol suppresses proliferation and invasion of gastric cancer cells via downregulation of microRNA-221 expression[J]. Genet Mol Res, 2015, 14(3): 8117-8124.
[7] Huang H, Benzonana LL, Zhao H, et al. Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination[J]. Br J Cancer, 2014, 111(7): 1338-1349.
[8] Wang P, Chen J, Mu LH, et al. Propofol inhibits invasion and enhances paclitaxel- induced apoptosis in ovarian cancer cells through the suppression of the transcription factor slug[J]. Eur Rev Med Pharmacol Sci, 2013, 17(13): 1722-1729.
[9] Wang XY, Li YL, Wang HY, et al. Propofol inhibits invasion and proliferation of C6 glioma cells by regulating the Ca2+ permeable AMPA receptor-system Xc-, pathway[J]. Toxicol In Vitro, 2017, 44: 57-65.
[10]Peng B, Li D, Qin M, et al. MicroRNA218 inhibits glioma migration and invasion via inhibiting glioma-associated oncogene homolog 1 expression at N terminus[J]. Tumor Biol, 2014, 35(4): 3831-3837.
[11]Zhu M, Chen L, Zhao P, et al. Store-operated Ca2+ entry regulates glioma cell migration and invasion via modulation of Pyk2 phosphorylation[J]. J Exp Clin Cancer Res, 2014, 33(1): 98-109.
[12]Horowitz M, Neeman E, Sharon E, et al. Exploiting the critical perioperative period to improve long-term cancer outcomes[J]. Nat Rev Clin Oncol, 2015, 12(4): 213-226.
[13]Priebe HJ. Aneurysmal subarachnoid haemorrhage and the anaesthetist[J]. Br J Anaesth, 2007, 99(1): 102-118.
[14]Su Z, Hou XK, Wen QP. Propofol induces apoptosis of epithelial ovarian cancer cells by upregulation of microRNA let-7i expression[J]. Eur J Gynaecol Oncol, 2014, 35(6): 688-691.
[15] Li LT, Jiang G, Chen Q, et al. Ki67 is a promising molecular target in the diagnosis of cancer (review)[J]. Mol Med Rep, 2015, 11(3): 1566-1572.
[16]Patel PB, Thakkar VR. L-carvone induces p53, caspase 3 mediated apoptosis and inhibits the migration of breast cancer cell lines[J]. Nutri Cancer, 2014, 66(3): 453-462.
[17] Ost P, Bossi A, Decaestecker K, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature[J]. Eur Urol, 2015, 67(5): 852-863.
[18]Wu KC, Yang ST, Hsia TC, et al. Suppression of cell invasion and migration by propofol are involved in down-regulating matrix metalloproteinase-2 and p38 MAPK signaling in A549 human lung adenocarcinoma epithelial cells[J]. Anticancer Res, 2012, 32(11): 4833-4842.
[19]Bai JJ, Lin CS, Ye HJ, et al. Propofol suppresses migration and invasion of breast cancer MDA-MB-231 cells by down-regulating H19[J]. Nan Fang Yi Ke Da Xue Xue Bao, 2016, 36(9):1255-1259.
[20]Enlund M, Berglund A, Andreasson K, et al. The choice of anaesthetic-sevoflurane or propofol-and outcome from cancer surgery: A retrospective analysis[J]. Ups J Med Sci, 2014, 119(3): 251-261.
[21] Li J, Li L, Li Z, et al. The role of miR-205 in the VEGF-mediated promotion of human ovarian cancer cell invasion[J]. Gynecol Oncol, 2015, 137(1): 125-133.
[22] Edlind MP, Hsieh AC. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance[J]. Asian J Androl, 2014, 16(3): 378-386.
[23] Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway[J]. Pharmacol Ther, 2014, 142(2): 164-175.
[24]Deng F, Ouyang M, Wang X, et al. Differential role of intravenous anesthetics in colorectal cancer progression: implications for clinical application[J]. Oncotarget, 2016, 7(47): 77087-77095. |